Healthequity Inc. Stock
€73.50
Your prediction
Healthequity Inc. Stock
Pros and Cons of Healthequity Inc. in the next few years
Pros
Cons
Performance of Healthequity Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Healthequity Inc. | - | -0.676% | 0.000% | 49.390% | 23.529% | 21.247% | - |
| Integer Hldg | 1.740% | 5.505% | 9.524% | 56.463% | 29.213% | 50.327% | 89.675% |
| Omnicell Inc. | -2.340% | 4.065% | -1.538% | -53.455% | -26.857% | -77.345% | -62.671% |
| Bruker Corp. | 1.360% | 4.119% | -10.651% | - | 15.549% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at the financial statements for the company HealthEquity, the clear impression is that the company has continued to grow its asset base over the years. Total assets have increased from around 2.71 billion USD in 2021 to around 3.08 billion USD in 2023, with significant portions being intangible assets and goodwill. That said, a close look at the income statements also reveals that this expansion has been met with a series of financial hurdles, from a swing in net income to a loss territory and intense research and development expenses.
One of the strengths of HealthEquity lies in its solid total asset growth. Increasing from 2.71 billion USD in 2021 to 3.08 billion USD in 2023, it shows the firm has been taking steps to expand. Furthermore, a significant portion of these are intangible assets and goodwill - indicating the company's acquisition of other companies or their intellectual property, which can be beneficial for long-term growth.
Continuously increasing gross profit, as revealed in the income statements of 2023 ($490,091,000), 2022 ($423,706,000), and 2021 ($415,334,000), paints a picture of strong sales and relatively controlled cost of goods sold. The free cash flow, especially in 2021 ($84,655,000), also gives a positive indication of the company’s capacity to generate healthy cash after catering for capital expenditures.